Recent Advances in Screening Methods Enabling the Discovery of Novel Anti-Hepatitis B Virus Drug Candidates

Yu Jin,Shuo Wang,Kai Tang,Peng Zhan,Xinyong Liu

DOI: https://doi.org/10.1016/j.ejmech.2024.117093

IF: 7.088

2024-01-01

European Journal of Medicinal Chemistry

Abstract:The global population affected by Hepatitis B virus (HBV) is approximately 296 million, but few drugs have been able to completely eradicate HBV and the range of effective treatments remains limited. Recent advancements in molecular biology and artificial intelligence, as well as a comprehensive understanding of the molecular structure of HBV, have greatly aided the rational development of anti-HBV agents. Such advancements have facilitated an increasing array of candidate drugs transitioning into clinical trials, however, no novel target-based compounds have been approved for clinical application. To expedite the progression of anti-HBV drug development, establishing a reliable and robust in vitro HBV infection system is of great importance. However, owing to the host and tissue specificity of HBV, identifying a stable and dependable cell culture system for screening all anti-HBV agents poses significant challenges. In this review, we summarize recent advances in screening methods for small-molecule inhibitors that target key stages of the HBV replication cycle from a medicinal chemistry perspective.